US Biotech at a Crossroads: Investors Warn DC on Innovation Policy

WASHINGTON, DC – March 24, 2026 – In a candid Capitol Hill roundtable, venture capital investors delivered a stark message to federal policymakers: the United States' long-held leadership in biotechnology is at a critical juncture, threatened by domestic policy proposals that could drive investment and innovation overseas. The meeting, convened by the venture capital coalition Incubate and the National Security Commission on Emerging Biotechnology (NSCEB), brought private investors face-to-face with congressional staff and national security experts to debate the delicate balance between healthcare affordability and maintaining a competitive edge in a field vital to both economic prosperity and national security.

The discussion highlighted a growing tension between the government's push for policies like international drug price controls and the private sector's need for a stable, predictable environment to justify the high-risk, long-term investments that fuel biomedical breakthroughs. Investors warned that without careful consideration, policies aimed at reducing costs could inadvertently dismantle the very ecosystem that has made the U.S. the world's premier destination for life sciences innovation.

A Warning from the Front Lines of Investment

The central theme of the roundtable was the fragility of the American biotech model, which relies on a steady flow of private capital into early-stage research and development. John Stanford, executive director of Incubate, articulated the industry's core concern. "The United States leads the world in biotechnology because we've built a system that supports long-term investment in high-risk, high-reward science," he stated. "Policies that import price controls, weaken intellectual property protections, or create regulatory uncertainty undermine that model."

This sentiment was echoed by a roster of prominent investors from firms including Forge Life Science Partners, Pfizer PAVE, Bessemer Venture Partners, and J.P. Morgan Life Science Private Capital. Their message was clear: capital is mobile, and if the U.S. policy landscape becomes inhospitable, investment will shift to competitors abroad. Stanford's warning underscored this point: "If we want the next generation of cures to be discovered and developed on American soil, policymakers must ensure the United States remains the best place in the world to invest in biomedical innovation."

From the national security perspective, NSCEB Vice Chair Dr. Michelle Rozo framed the issue as an opportunity to unleash a key American advantage. "Private capital has been stuck on the sidelines of certain biotech development for too long, and this discussion highlighted the importance of solving that problem," Rozo said. She argued that the solution lies not in stifling the market but in enabling it. "With smart regulatory reforms and strategic government investment, we can reduce the risk for investors and mobilize more private investment in this critical sector. Our strong private markets are our key advantage in accelerating and securing biotechnology – it’s time to unleash them."

The Specter of Global Competition

The urgency of the discussion is amplified by a stark geopolitical reality. The NSCEB's comprehensive April 2025 report, "Charting the Future of Biotechnology," concluded that the U.S. is "dangerously close to falling behind China" after two decades of strategic, state-funded prioritization by Beijing. The report paints a picture of a global race where the U.S. can no longer take its leadership for granted.

China has designated biotechnology a national priority, pouring billions into research, talent acquisition, and building domestic supply chains to reduce its reliance on foreign technology and control access to vital biological data and materials. This state-directed strategy stands in sharp contrast to the U.S. model, which is predominantly driven by private venture capital and a vibrant startup culture. While the American system has historically proven more dynamic and innovative, experts warn it is more sensitive to market signals and policy shifts.

The NSCEB report laid out 49 recommendations to counter this threat, including the establishment of a National Biotechnology Coordination Office within the White House to streamline federal efforts. The commission's findings suggest that failing to act decisively could compromise not only future economic growth but also national security, particularly by increasing reliance on a strategic competitor for essential medicines and biomanufacturing capabilities.

Policy Headwinds Facing Innovators

Investors at the roundtable detailed a trio of policy concerns that are creating significant uncertainty and chilling investment in the U.S. biotech sector. The most prominent among them is the ongoing debate over drug pricing, particularly proposals for "Most Favored Nation"-style international reference pricing. Such policies would peg U.S. drug prices to lower rates paid in other countries. While proponents argue this is necessary for affordability, investors contend it would slash revenues and drastically reduce the capital available for R&D. The Congressional Budget Office has itself projected that similar pricing provisions in the Inflation Reduction Act will likely lead to fewer new drugs coming to market over the next three decades.

Closely linked to pricing is the strength of intellectual property (IP) protections. For venture capitalists, patents are the bedrock of their investment thesis, guaranteeing a period of market exclusivity to recoup the immense costs and risks of drug development. They argue that price controls effectively devalue this IP, diminishing the incentive to fund the next generation of therapies, especially for rare diseases or complex conditions.

Finally, the participants highlighted the persistent challenges of navigating the Food and Drug Administration (FDA). While respected for its gold-standard safety and efficacy reviews, the agency is perceived by many in the industry as understaffed and struggling to keep pace with the science. Regulatory uncertainty, unclear pathways for novel technologies like cell and gene therapies, and unpredictable review timelines can add years and millions of dollars to a product's development, making many promising but complex projects too risky for private funding. This regulatory friction acts as a major bottleneck, slowing the translation of lab discoveries into patient cures and creating a drag on capital allocation. The dialogue on Capitol Hill signals a growing recognition that these domestic policy debates are no longer happening in a vacuum, as the decisions made in Washington will directly influence America's standing in the global bioindustrial revolution.